



Areacor Therapeutics plc
("Areacor" or the "Group")

TETRIS PHARMA ANNOUNCES COMMERCIALISATION AGREEMENT WITH GOODLIFE

Cambridge, UK, 4 September 2023: Areacor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, announces that subsidiary company, Tetris Pharma Ltd has established an exclusive commercialisation agreement with Goodlife, who will act as sole partner for the import, marketing and distribution of Ogluo® in the BeNeLux region.

See full Tetris Pharma announcement below:

Tetris Pharma announces commercialisation agreement with Goodlife

Partnership to drive accelerated market adoption of Ogluo in BeNeLux region

4 September 2023 - Tetris Pharma Ltd ("Tetris Pharma" or "the Company"), a subsidiary of biopharmaceutical company, Areacor Therapeutics plc (AIM: AREC), today announces that it has established an exclusive commercialisation agreement with Goodlife, who will act as sole partner for the import, marketing and distribution of Ogluo® (glucagon prefilled autoinjector pen) in the BeNeLux region.

The Zorginstiut Nederland (the National Healthcare Institute of The Netherlands) has approved Ogluo® at the requested price on List 1B and Goodlife is expected to launch the product in The Netherlands during H1 2024.

Sarah Howell, Chief Executive Officer at Areacor, said: *"Goodlife provides the commercial expertise and detailed understanding of regional market dynamics that are essential for the Company's continued roll-out of Ogluo® and its market adoption in the BeNeLux region. The upcoming launch in The Netherlands adds to existing markets in the UK, Germany, Austria, Denmark and Norway, as part of the planned on-going pan-European commercial roll-out for this important product."*

Koen Perenboom, Managing Director, Goodlife, said: *"With more than a quarter of a million people living with insulin-treated diabetes and at risk of severe hypoglycaemia in The Netherlands, Ogluo is an important treatment option for people with diabetes and their caregivers, that can provide them with the confidence to*



manage severe hypoglycaemic events. This strategic collaboration with Arecor symbolises our mutual commitment to provide every individual patient excellent care.”

About Ogluo®:

Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon in an auto-injector for patients within the licenced indication living with diabetes suffering from severe hypoglycaemia¹. Hypoglycaemia is a common and serious complication of diabetes, particularly affecting people with diabetes on insulin treatment. It is characterised by abnormally low blood sugar levels, which can lead to cognitive impairment and in some severe cases, seizures, loss of consciousness, coma and even death. It can have a profound effect on the everyday lives of people with diabetes and their caregivers². The European Commission granted the marketing authorization for Ogluo® on 11 February 2021.

1. *Ogluo SmPC*
2. Amiel, S.A. The consequences of hypoglycaemia. *Diabetologia* **64**, 963-970 (2021). <https://doi.org/10.1007/s00125-020-05366-3>

Notes to Editors

Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a commercial-stage specialty pharmaceutical company with expertise in registering, marketing, sales and the distribution of speciality hospital products across the UK and Europe. Our experienced team has a proven history of building and growing sales. Having secured distribution rights for already licensed products across Europe, we have a portfolio of niche injectable products including Ogluo®, a ready-to-use glucagon for emergency use to treat hypoglycaemia. We collaborate with partners to provide patients with effective treatments and quality healthcare by ensuring we deliver accountability, partnership and performance. For further information, please visit www.tetrispharma.com.

Goodlife is a privately owned pharmaceutical company with a focus on The Netherlands, Belgium and Luxembourg. Goodlife believes that every patient deserves excellent care that matches their individual needs, even if those needs deviate from the norm. With this in mind, we strive for customization every day, by providing unique medicines, medical devices, dietary supplements and supportive tools for individual patients in the BeNeLux. For more information, please visit www.goodlifepharma.com.

-ENDS-



For more information, please contact:

Areacor Therapeutics plc

Dr Sarah Howell, Chief Executive Officer

www.arecor.com

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email: mo.noonan@arecor.com

Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

Consilium Strategic Communications

Chris Gardner, David Daley, Lindsey Neville

Tel: +44 (0) 20 3709 5700

Email: arecor@consilium-comms.com

Notes to Editors

About Areacor

Areacor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com